Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.

BACKGROUND Identifying predictors of conversion to Alzheimer's disease (AD) is critically important for AD prevention and targeted treatment. OBJECTIVE To compare various clinical and biomarker trajectories for tracking progression and predicting conversion from amnestic mild cognitive impairment to probable AD. METHODS Participants were from the ADNI-1 study. We assessed the ability of 33 longitudinal biomarkers to predict time to AD conversion, accounting for demographic and genetic factors. We used joint modelling of longitudinal and survival data to examine the association between changes of measures and disease progression. We also employed time-dependent receiver operating characteristic method to assess the discriminating capability of the measures. RESULTS 23 of 33 longitudinal clinical and imaging measures are significant predictors of AD conversion beyond demographic and genetic factors. The strong phenotypic and biological predictors are in the cognitive domain (ADAS-Cog; RAVLT), functional domain (FAQ), and neuroimaging domain (middle temporal gyrus and hippocampal volume). The strongest predictor is ADAS-Cog 13 with an increase of one SD in ADAS-Cog 13 increased the risk of AD conversion by 2.92 times. CONCLUSION Prediction of AD conversion can be improved by incorporating longitudinal change information, in addition to baseline characteristics. Cognitive measures are consistently significant and generally stronger predictors than imaging measures.

[1]  M. Stone.  Asymptotics for and against cross-validation , 1977 .

[2]  D. Thomas,et al.  Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. , 1996, Statistics in medicine.

[3]  M. Wulfsohn,et al.  A joint model for survival and longitudinal data measured with error. , 1997, Biometrics.

[4]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[5]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[6]  Sara Rosenblum,et al.  Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. , 2006, Archives of general psychiatry.

[7]  A. Fleisher,et al.  Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment , 2007, Neurology.

[8]  Deborah Blacker,et al.  Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. , 2007, Archives of general psychiatry.

[9]  Yaakov Stern,et al.  Frequency and course of mild cognitive impairment in a multiethnic community , 2008, Annals of neurology.

[10]  C. Jack,et al.  Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment , 2008, Neurology.

[11]  H M Huizenga,et al.  Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease , 2009, Psychological Medicine.

[12]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[13]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[14]  A. Dale,et al.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease , 2009, Human brain mapping.

[15]  S. Resnick,et al.  Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. , 2009, Brain : a journal of neurology.

[16]  S. de Santi,et al.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. , 2010, Journal of Alzheimer's disease : JAD.

[17]  Dimitris Rizopoulos,et al.  JM: An R package for the joint modelling of longitudinal and time-to-event data , 2010 .

[18]  Joseph G Ibrahim,et al.  Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[20]  A. Dale,et al.  CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease , 2010, The Journal of Neuroscience.

[21]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[22]  Jesse S. Jin,et al.  Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors , 2011, PloS one.

[23]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[24]  Dimitris Rizopoulos,et al.  Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time‐to‐Event Data , 2011, Biometrics.

[25]  R. Chapman,et al.  Please Scroll down for Article Journal of Clinical and Experimental Neuropsychology Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Neuropsychological Tests and Multivariate Methods , 2022 .

[26]  Alan E Hubbard,et al.  Longitudinal change of biomarkers in cognitive decline. , 2011, Archives of neurology.

[27]  T. Goldberg,et al.  Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. , 2011, Archives of general psychiatry.

[28]  C. Jack,et al.  Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance , 2012, Neurobiology of Aging.

[29]  Dimitris Rizopoulos,et al.  Joint Models for Longitudinal and Time-to-Event Data: With Applications in R , 2012 .

[30]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[31]  Daoqiang Zhang,et al.  Predicting Future Clinical Changes of MCI Patients Using Longitudinal and Multimodal Biomarkers , 2012, PloS one.

[32]  Bruno Vellas,et al.  Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force , 2013, Alzheimer's & Dementia.

[33]  Marilyn Albert,et al.  Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up. , 2013, American journal of Alzheimer's disease.

[34]  M. Albert,et al.  Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. , 2014, Current Alzheimer research.

[35]  Alzheimer's Disease Neuroimaging Initiative,et al.  A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease , 2014, Alzheimer's & Dementia.

[36]  D. Salmon,et al.  Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[37]  D. Berry,et al.  Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease , 2015, Alzheimer disease and associated disorders.

[38]  S. Luo,et al.  Joint modeling of multivariate longitudinal measurements and survival data with applications to Parkinson’s disease , 2016, Statistical methods in medical research.

[39]  Liang Li,et al.  DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE. , 2016, The annals of applied statistics.

[40]  Chengjie Xiong,et al.  The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.